Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection
Adam Stafford, Stephanie Rimmer, Mark Gilchrist, Kristi Sun, Ella Davies, Claire S. Waddington, Christopher Chiu, Darius Armstrong‐James, Thomas Swaine, Frances Davies, Carlos H M Gómez, Vagish Kumar, Ahmad ElHaddad, Zaid Awad, Christopher Smart, Borja Mora‐Peris, David Muir, Paul Randell, Joanna Peters, Meera Chand, Clare E. Warrell, Tommy Rampling, Graham Cooke, Sara Dhanji, Vivienne Campbell, Carys Ann Davies, Sana Osman, Aula Abbara
Abstract
A 48-year-old man with poorly controlled HIV presented with severe human monkeypox virus (hMPXV) infection, having completed 2 weeks of tecovirimat at another hospital. He had painful, ulcerating skin lesions on most of his body and oropharyngeal cavity, with subsequent Ludwig's angina requiring repeated surgical interventions. Despite commencing a second, prolonged course of tecovirimat, he did not objectively improve, and new lesions were still noted at day 24. Discussion at the UK National Health Service England High Consequence Infectious Diseases Network recommended the use of 3% topical and then intravenous cidofovir, which was given at 5 mg/kg; the patient made a noticeable improvement after the first intravenous dose. He received further intravenous doses at 7 days and 21 days after the dose and was discharged at day 52. Cidofovir is not licensed for use in treatment of hMPXV infection. Data for cidofovir use in hMPXV are restricted to studies in animals. Four other documented cases of cidofovir use against hMPXV have been reported in the USA in 2022, but we present its first use in the UK. The scarcity of studies into the use of cidofovir in this condition clearly shows the need for robust studies to assess efficacy, optimum dosage, timing, and route of administration.